The NCI mandates that all CCSG-funded cancer centers establish a protocol review and monitoring system for oversight of the clinical research conducted at that institution. At the USC Norris Comprehensive Cancer Center (NCCC), the Clinical Investigations Committee (CIC) has this responsibility. The CIC performs the scientific review of proposed cancer clinical studies, and oversees the conduct of all clinical studies open at the NCCC. To facilitate the oversight of open trials, the internal Data and Safety Monitoring Committee (DSMC) will meet monthly to review institutional clinical trials (i.e., cancer-related trials involving an intervention where a USC investigator is the overall principal investigator (PI) of the study and the trial is not part of a national cooperative group or the CCCP Consortium, or sponsored by a pharmaceutical company that will responsible for the data management and oversight of the progress of the trial). Each in-house trial will be reviewed annually or more frequently as determined by the CIC. The reviews of the DSMC complement those of the QAMC, a long-standing Cancer Center committee which is charged with (among other responsibilities) reviewing accrual, and SAE's and major violations in a timely fashion, for all open protocols, as well as conducting audits of patients on institutional clinical trials. The DSMC will work in close coordination with the Clinical Investigations Support Office, which plays the main role of coordinating the conduct of clinical research in the NCCC. The objectives of the DSMC are to: 1. review, at established intervals, safety and aspects of the protocol and study conduct that may impact on safety of current or future patients 2. review all serious adverse events or other adverse events that require expedited reporting 3. review the progress of the study 4. review efficacy results that trigger early closure or early reporting 5. review the completeness and the quality of the research data 6. report the results of each review and make recommendations to the study PI, IRB, the Quality Assurance Monitoring Committee and the CIC.
It is the responsibility of the NCCC to ensure that the trials undertaken at the Cancer Center are scientifically sound and conducted in a rigorous fashion so as to yield timely and meaningful data in order to advance the development of effective diagnostics and treatments. The DSMC will monitor the safety of NCCC institutional trials to ensure patient safety and timely study completion with high quality results.
|Lawrenson, Kate; Grun, Barbara; Lee, Nathan et al. (2015) NPPB is a novel candidate biomarker expressed by cancer-associated fibroblasts in epithelial ovarian cancer. Int J Cancer 136:1390-401|
|Milam, Joel E; Meeske, Kathleen; Slaughter, Rhona I et al. (2015) Cancer-related follow-up care among Hispanic and non-Hispanic childhood cancer survivors: The Project Forward study. Cancer 121:605-13|
|Maus, M K H; Hanna, D L; Stephens, C L et al. (2015) Distinct gene expression profiles of proximal and distal colorectal cancer: implications for cytotoxic and targeted therapy. Pharmacogenomics J 15:354-62|
|Hirsch, Louis; Nazari, Hossein; Sreekumar, Parameswaran G et al. (2015) TGF-?2 secretion from RPE decreases with polarization and becomes apically oriented. Cytokine 71:394-6|
|Chuh, Kelly N; Pratt, Matthew R (2015) Chemical methods for the proteome-wide identification of posttranslationally modified proteins. Curr Opin Chem Biol 24:27-37|
|Zhang, Hongjun; Boddupally, Keerthi; Kandyba, Eve et al. (2014) Defining the localization and molecular characteristic of minor salivary gland label-retaining cells. Stem Cells 32:2267-77|
|Wu, Dai-Ying; Ou, Chen-Yin; Chodankar, Rajas et al. (2014) Distinct, genome-wide, gene-specific selectivity patterns of four glucocorticoid receptor coregulators. Nucl Recept Signal 12:e002|
|Su, Sheng-Fang; de Castro Abreu, André Luís; Chihara, Yoshitomo et al. (2014) A panel of three markers hyper- and hypomethylated in urine sediments accurately predicts bladder cancer recurrence. Clin Cancer Res 20:1978-89|
|Tai, Kenneth P; Le, Valerie V; Selsted, Michael E et al. (2014) Hydrophobic determinants of ?-defensin bactericidal activity. Infect Immun 82:2195-202|
|Ng, Yuen-Keng; Lee, Jia-Ying; Supko, Kathryn M et al. (2014) Pan-erbB inhibition potentiates BRAF inhibitors for melanoma treatment. Melanoma Res 24:207-18|
Showing the most recent 10 out of 345 publications